Paradigm Medical Industries Plans to Begin Clinical Work to Upgrade Its CPT Code for Its Blood Flow Analyzer From an Investigati

  Paradigm Medical Industries, Inc.
(OTCBB: PDMI) announced today that the Company plans to begin the important
process of upgrading its CPT code (0189T) for its Blood Flow Analyzer from
the American Medical Association from an investigational level (Class III)
to one that will enable public and private medical centers to be reimbursed
by their regional medical insurance companies for testing patients using
the Blood Flow Analyzer. The Blood Flow Analyzer is used to detect glaucoma
and aid in managing the disease.

Current Procedural Terminology (CPT) coding is a standard, universal code that is applied to medical procedures and services for the purpose of patient records. CPT is to provide a uniform language that accurately describes medical, surgical, and diagnostic services, and thereby serves as an effective means for reliable nationwide communication among physicians, and other healthcare providers, patients and third parties. Receiving a reimbursable CPT Code will be an important step towards the Blood Flow Analyzer's acceptance as a standard diagnostic instrument in early detection of glaucoma in patients.

"We are confident that by taking the next important clinical steps to complete the process of upgrading this CPT code to a reimbursable level, both public and private payers will be encouraged to reimburse physicians for utilizing the Blood Flow Analyzer," said Paradigm Medical President Stephen Davis. "Moving the Blood Flow Analyzer from an investigational level to an acceptable diagnostic procedure will benefit patients and physicians alike by offering earlier glaucoma diagnosis and treatment."

About Paradigm Medical Industries, Inc.

Headquartered in Salt Lake City, UT, Paradigm Medical Industries, Inc. is a medical device company that develops, manufactures and distributes cutting edge, new innovative products in the diagnostic ultrasound and early glaucoma detection markets. Paradigm has the only patented technology utilizing photon laser for cataract removal. The Company is poised to capture a niche market within the Glaucoma and ultrasound microscopy fields. Paradigm Medical Industries markets its products to ophthalmologists, optometrists, universities, and clinics throughout the United States, as well as internationally.

For more information, please visit: www.paradigm-medical.com

This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.

Contact: Paradigm Medical Industries, Inc. Stephen Davis President 801-977-8970 www.paradigm-medical.com